Prelude Therapeutics’ (PRLD) Market Outperform Rating Reiterated at JMP Securities
JMP Securities reaffirmed their market outperform rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a research note published on Tuesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock. Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Prelude Therapeutics in a […]
JMP Securities reaffirmed their market outperform rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a research note published on Tuesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock. Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Prelude Therapeutics in a […]
